IDEXX Laboratories, Inc. $IDXX Shares Sold by LGT Capital Partners LTD.

LGT Capital Partners LTD. lowered its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 105,998 shares of the company’s stock after selling 14,327 shares during the quarter. IDEXX Laboratories comprises about 3.6% of LGT Capital Partners LTD.’s investment portfolio, making the stock its 9th biggest holding. LGT Capital Partners LTD.’s holdings in IDEXX Laboratories were worth $71,711,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Westerkirk Capital Inc. raised its position in IDEXX Laboratories by 69.2% during the fourth quarter. Westerkirk Capital Inc. now owns 2,112 shares of the company’s stock worth $1,429,000 after acquiring an additional 864 shares during the last quarter. Gordian Capital Singapore Pte Ltd raised its position in IDEXX Laboratories by 260.0% during the fourth quarter. Gordian Capital Singapore Pte Ltd now owns 900 shares of the company’s stock worth $609,000 after acquiring an additional 650 shares during the last quarter. Cerity Partners LLC raised its position in IDEXX Laboratories by 6.6% during the fourth quarter. Cerity Partners LLC now owns 22,705 shares of the company’s stock worth $15,361,000 after acquiring an additional 1,410 shares during the last quarter. LPL Financial LLC raised its position in IDEXX Laboratories by 14.6% during the fourth quarter. LPL Financial LLC now owns 45,636 shares of the company’s stock worth $30,874,000 after acquiring an additional 5,813 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in IDEXX Laboratories by 9.5% during the fourth quarter. Franklin Resources Inc. now owns 627,159 shares of the company’s stock worth $424,291,000 after acquiring an additional 54,181 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $561.17 on Tuesday. The firm has a 50 day simple moving average of $562.81 and a 200-day simple moving average of $631.11. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The firm has a market cap of $44.27 billion, a PE ratio of 41.32, a P/E/G ratio of 3.08 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on IDXX shares. UBS Group cut their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Piper Sandler cut their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.